Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.

Wiese AB, Berrocal VJ, Furst DE, Seibold JR, Merkel PA, Mayes MD, Khanna D.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1731-9. doi: 10.1002/acr.22339.

2.

Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial.

Khanna PP, Furst DE, Clements PJ, Maranian P, Indulkar L, Khanna D; D-Penicillamine Investigators.

Rheumatology (Oxford). 2010 May;49(5):955-9. doi: 10.1093/rheumatology/kep464. Epub 2010 Feb 9.

3.

Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

Wallace B, Kafaja S, Furst DE, Berrocal VJ, Merkel PA, Seibold JR, Mayes MD, Khanna D.

Rheumatology (Oxford). 2015 Aug;54(8):1369-79. doi: 10.1093/rheumatology/keu456. Epub 2015 Feb 9.

4.

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2012 Oct;64(10):3420-9. doi: 10.1002/art.34427.

5.

The correlation between durometer score and modified Rodnan skin score in systemic sclerosis.

Moon KW, Song R, Kim JH, Lee EY, Lee EB, Song YW.

Rheumatol Int. 2012 Aug;32(8):2465-70. doi: 10.1007/s00296-011-1993-9. Epub 2011 Jul 19.

PMID:
21769489
6.

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.

Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, Allanore Y, Distler O; EUSTAR coauthors.

Ann Rheum Dis. 2016 Oct;75(10):1743-8. doi: 10.1136/annrheumdis-2015-208024. Epub 2016 Mar 25.

7.

Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.

Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM, Korn JH; CAT-192 Research Group; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2008 May 15;59(5):699-705. doi: 10.1002/art.23564.

8.

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.

Maurer B, Graf N, Michel BA, Müller-Ladner U, Czirják L, Denton CP, Tyndall A, Metzig C, Lanius V, Khanna D, Distler O; EUSTAR co-authors.

Ann Rheum Dis. 2015 Jun;74(6):1124-31. doi: 10.1136/annrheumdis-2014-205226. Epub 2014 Jun 30.

PMID:
24981642
9.

Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium.

J Rheumatol. 2005 May;32(5):832-40.

PMID:
15868618
10.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2002 Sep;46(9):2410-20.

11.

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.

Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D; Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials.

Arthritis Rheum. 2009 Aug;60(8):2490-8. doi: 10.1002/art.24681.

12.

Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.

Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, Denton CP.

Arthritis Rheum. 2007 Jul;56(7):2422-31.

13.
14.

A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis.

Sandqvist G, Hesselstrand R, Eberhardt K.

Scand J Rheumatol. 2009;38(4):304-10. doi: 10.1080/03009740802695466.

PMID:
19296402
15.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Rheumatol. 2016 Feb;68(2):299-311. doi: 10.1002/art.39501.

16.

Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis.

Doré A, Lucas M, Ivanco D, Medsger TA Jr, Domsic RT.

Arthritis Care Res (Hoboken). 2013 Aug;65(8):1385-9. doi: 10.1002/acr.21964.

17.

The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile.

Vanthuyne M, Smith V, De Langhe E, Van Praet J, Arat S, Depresseux G, Westhovens R, Blockmans D, Badot V, Cogan E, De Keyser F, Houssiau FA.

J Rheumatol. 2012 Nov;39(11):2127-33. doi: 10.3899/jrheum.120283. Epub 2012 Sep 15.

PMID:
22984273
18.

A preliminary study of acoustic radiation force impulse quantification for the assessment of skin in diffuse cutaneous systemic sclerosis.

Hou Y, Zhu QL, Liu H, Jiang YX, Wang L, Xu D, Li MT, Zeng XF, Zhang FC.

J Rheumatol. 2015 Mar;42(3):449-55. doi: 10.3899/jrheum.140873. Epub 2015 Jan 15.

PMID:
25593239
19.

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.

Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, Medsger TA Jr.

Arthritis Rheum. 2007 Aug;56(8):2740-6.

20.

Self-assessment of disease activity by patients with rheumatoid arthritis.

Hanly JG, Mosher D, Sutton E, Weerasinghe S, Theriault D.

J Rheumatol. 1996 Sep;23(9):1531-8.

PMID:
8877920

Supplemental Content

Support Center